Aliskiren improves Ischemia- and oxygen glucose deprivation-induced cardiac injury through activation of autophagy and AMP-activated protein kinase

Ming Hsien Chiang, Chan Jung Liang, Chen Wei Liu, Bo Jhih Pan, Wen Ping Chen, Yi Fan Yang, I-Ta Lee, Jaw Shiun Tsai, Chiang Wen Lee, Yuh Lien Chen

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Aliskiren is a direct renin inhibitor that has been effective in anti-hypertension. We investigated whether aliskiren could improve the ischemia-induced cardiac injury and whether the autophagy was involved in this effect. A myocardial infarction (MI) model was created by the ligation of the left anterior coronary artery in C57J/BL6 mice. They were treated for 1, 3, 7, and 14 days with vehicle or aliskiren (25 mg/kg/day via subcutaneous injection). In vivo, the MI mice exhibited worse cardiac function by echocardiographic assessment and showed larger myocardial scarring by light microscopy, whereas aliskiren treatment reversed these effects, which were also associated with the changes in caspase-3 and Bcl-2 expression as well as in the number of apoptotic cells. Aliskiren increased autophagy, as demonstrated by LC3B-II expression and transmission electron microscopy. Furthermore, H9c2 cardiomyocytes were employed as an in vitro model to examine the effects of aliskiren on apoptosis and autophagy under oxygen glucose deprivation (OGD)-induced injury. Aliskiren significantly increased cell viability in a dose-dependent manner. The beneficial effects of aliskiren were associated with decreased apoptosis and mitochondrial membrane potential as well as increased autophagy via increased autophagosome formation. We also found that aliskiren-induced cardiomyocyte survival occurred via AMP-activated protein kinase (AMPK)-dependent autophagy. Taken together, these results indicated that aliskiren increased cardiomyocyte survival through increased autophagosomal formation and decreased apoptosis and necrosis via modulating AMPK expression. AMPK-dependent autophagy may represent a novel mechanism for aliskiren in ischemic cardiac disease therapy.

Original languageEnglish
Article number819
JournalFrontiers in Pharmacology
Volume8
Issue numberNOV
DOIs
Publication statusPublished - Nov 14 2017
Externally publishedYes

Fingerprint

AMP-Activated Protein Kinases
Autophagy
Ischemia
Oxygen
Glucose
Wounds and Injuries
Cardiac Myocytes
Apoptosis
aliskiren
Myocardial Infarction
Mitochondrial Membrane Potential
Subcutaneous Injections
Transmission Electron Microscopy
Renin
Caspase 3
Cicatrix
Ligation
Microscopy
Heart Diseases
Cell Survival

Keywords

  • Aliskiren
  • Apoptosis
  • Autophagy
  • Cardiac injury
  • Oxygen glucose deprivation (OGD)

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)

Cite this

Aliskiren improves Ischemia- and oxygen glucose deprivation-induced cardiac injury through activation of autophagy and AMP-activated protein kinase. / Chiang, Ming Hsien; Liang, Chan Jung; Liu, Chen Wei; Pan, Bo Jhih; Chen, Wen Ping; Yang, Yi Fan; Lee, I-Ta; Tsai, Jaw Shiun; Lee, Chiang Wen; Chen, Yuh Lien.

In: Frontiers in Pharmacology, Vol. 8, No. NOV, 819, 14.11.2017.

Research output: Contribution to journalArticle

Chiang, Ming Hsien ; Liang, Chan Jung ; Liu, Chen Wei ; Pan, Bo Jhih ; Chen, Wen Ping ; Yang, Yi Fan ; Lee, I-Ta ; Tsai, Jaw Shiun ; Lee, Chiang Wen ; Chen, Yuh Lien. / Aliskiren improves Ischemia- and oxygen glucose deprivation-induced cardiac injury through activation of autophagy and AMP-activated protein kinase. In: Frontiers in Pharmacology. 2017 ; Vol. 8, No. NOV.
@article{1f6d327373ed4774846a321f30dccf51,
title = "Aliskiren improves Ischemia- and oxygen glucose deprivation-induced cardiac injury through activation of autophagy and AMP-activated protein kinase",
abstract = "Aliskiren is a direct renin inhibitor that has been effective in anti-hypertension. We investigated whether aliskiren could improve the ischemia-induced cardiac injury and whether the autophagy was involved in this effect. A myocardial infarction (MI) model was created by the ligation of the left anterior coronary artery in C57J/BL6 mice. They were treated for 1, 3, 7, and 14 days with vehicle or aliskiren (25 mg/kg/day via subcutaneous injection). In vivo, the MI mice exhibited worse cardiac function by echocardiographic assessment and showed larger myocardial scarring by light microscopy, whereas aliskiren treatment reversed these effects, which were also associated with the changes in caspase-3 and Bcl-2 expression as well as in the number of apoptotic cells. Aliskiren increased autophagy, as demonstrated by LC3B-II expression and transmission electron microscopy. Furthermore, H9c2 cardiomyocytes were employed as an in vitro model to examine the effects of aliskiren on apoptosis and autophagy under oxygen glucose deprivation (OGD)-induced injury. Aliskiren significantly increased cell viability in a dose-dependent manner. The beneficial effects of aliskiren were associated with decreased apoptosis and mitochondrial membrane potential as well as increased autophagy via increased autophagosome formation. We also found that aliskiren-induced cardiomyocyte survival occurred via AMP-activated protein kinase (AMPK)-dependent autophagy. Taken together, these results indicated that aliskiren increased cardiomyocyte survival through increased autophagosomal formation and decreased apoptosis and necrosis via modulating AMPK expression. AMPK-dependent autophagy may represent a novel mechanism for aliskiren in ischemic cardiac disease therapy.",
keywords = "Aliskiren, Apoptosis, Autophagy, Cardiac injury, Oxygen glucose deprivation (OGD)",
author = "Chiang, {Ming Hsien} and Liang, {Chan Jung} and Liu, {Chen Wei} and Pan, {Bo Jhih} and Chen, {Wen Ping} and Yang, {Yi Fan} and I-Ta Lee and Tsai, {Jaw Shiun} and Lee, {Chiang Wen} and Chen, {Yuh Lien}",
year = "2017",
month = "11",
day = "14",
doi = "10.3389/fphar.2017.00819",
language = "English",
volume = "8",
journal = "Frontiers in Pharmacology",
issn = "1663-9812",
publisher = "Frontiers Media S. A.",
number = "NOV",

}

TY - JOUR

T1 - Aliskiren improves Ischemia- and oxygen glucose deprivation-induced cardiac injury through activation of autophagy and AMP-activated protein kinase

AU - Chiang, Ming Hsien

AU - Liang, Chan Jung

AU - Liu, Chen Wei

AU - Pan, Bo Jhih

AU - Chen, Wen Ping

AU - Yang, Yi Fan

AU - Lee, I-Ta

AU - Tsai, Jaw Shiun

AU - Lee, Chiang Wen

AU - Chen, Yuh Lien

PY - 2017/11/14

Y1 - 2017/11/14

N2 - Aliskiren is a direct renin inhibitor that has been effective in anti-hypertension. We investigated whether aliskiren could improve the ischemia-induced cardiac injury and whether the autophagy was involved in this effect. A myocardial infarction (MI) model was created by the ligation of the left anterior coronary artery in C57J/BL6 mice. They were treated for 1, 3, 7, and 14 days with vehicle or aliskiren (25 mg/kg/day via subcutaneous injection). In vivo, the MI mice exhibited worse cardiac function by echocardiographic assessment and showed larger myocardial scarring by light microscopy, whereas aliskiren treatment reversed these effects, which were also associated with the changes in caspase-3 and Bcl-2 expression as well as in the number of apoptotic cells. Aliskiren increased autophagy, as demonstrated by LC3B-II expression and transmission electron microscopy. Furthermore, H9c2 cardiomyocytes were employed as an in vitro model to examine the effects of aliskiren on apoptosis and autophagy under oxygen glucose deprivation (OGD)-induced injury. Aliskiren significantly increased cell viability in a dose-dependent manner. The beneficial effects of aliskiren were associated with decreased apoptosis and mitochondrial membrane potential as well as increased autophagy via increased autophagosome formation. We also found that aliskiren-induced cardiomyocyte survival occurred via AMP-activated protein kinase (AMPK)-dependent autophagy. Taken together, these results indicated that aliskiren increased cardiomyocyte survival through increased autophagosomal formation and decreased apoptosis and necrosis via modulating AMPK expression. AMPK-dependent autophagy may represent a novel mechanism for aliskiren in ischemic cardiac disease therapy.

AB - Aliskiren is a direct renin inhibitor that has been effective in anti-hypertension. We investigated whether aliskiren could improve the ischemia-induced cardiac injury and whether the autophagy was involved in this effect. A myocardial infarction (MI) model was created by the ligation of the left anterior coronary artery in C57J/BL6 mice. They were treated for 1, 3, 7, and 14 days with vehicle or aliskiren (25 mg/kg/day via subcutaneous injection). In vivo, the MI mice exhibited worse cardiac function by echocardiographic assessment and showed larger myocardial scarring by light microscopy, whereas aliskiren treatment reversed these effects, which were also associated with the changes in caspase-3 and Bcl-2 expression as well as in the number of apoptotic cells. Aliskiren increased autophagy, as demonstrated by LC3B-II expression and transmission electron microscopy. Furthermore, H9c2 cardiomyocytes were employed as an in vitro model to examine the effects of aliskiren on apoptosis and autophagy under oxygen glucose deprivation (OGD)-induced injury. Aliskiren significantly increased cell viability in a dose-dependent manner. The beneficial effects of aliskiren were associated with decreased apoptosis and mitochondrial membrane potential as well as increased autophagy via increased autophagosome formation. We also found that aliskiren-induced cardiomyocyte survival occurred via AMP-activated protein kinase (AMPK)-dependent autophagy. Taken together, these results indicated that aliskiren increased cardiomyocyte survival through increased autophagosomal formation and decreased apoptosis and necrosis via modulating AMPK expression. AMPK-dependent autophagy may represent a novel mechanism for aliskiren in ischemic cardiac disease therapy.

KW - Aliskiren

KW - Apoptosis

KW - Autophagy

KW - Cardiac injury

KW - Oxygen glucose deprivation (OGD)

UR - http://www.scopus.com/inward/record.url?scp=85033781596&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85033781596&partnerID=8YFLogxK

U2 - 10.3389/fphar.2017.00819

DO - 10.3389/fphar.2017.00819

M3 - Article

VL - 8

JO - Frontiers in Pharmacology

JF - Frontiers in Pharmacology

SN - 1663-9812

IS - NOV

M1 - 819

ER -